Drug Profile
MEDI 9287
Alternative Names: Avian influenza vaccine - AstraZeneca; H7N9 vaccine - AstraZeneca; Influenza A virus vaccine H7N9 - AstraZeneca; MEDI-9287Latest Information Update: 01 Sep 2014
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H7N9 subtype
Most Recent Events
- 31 Jul 2014 Discontinued - Phase-I for Influenza-A virus H7N9 subtype in USA (unspecified route)
- 31 Mar 2014 AstraZeneca establishes CRADA with NIH for the development of MEDI 9287 in Influenza A virus H7N9 subtype prior to March 2014
- 12 Dec 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype in USA (unspecified route)